You just read:

Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA

News provided by

Abbott

06 Nov, 2011, 11:00 GMT